Healthpoint today announced its acquisition of two cellbased technologies from Intercytex Limited along with the corresponding intellectual property (including patents), validated fibroblast and keratinocyte cell banks, and related production and testing equipment. Terms of the deal were not disclosed by Healthpoint.

The therapeutic candidates acquired include CYZACT™--human dermal fibroblasts delivered via a fibrin sheet and produced utilizing a streamlined manufacturing process as compared to similar products—and ICX-SKN--a combination of fibroblasts and fibrin matrix that are remodeled to produce a collagen matrix that allows the engineered tissue to remain intact in a hostile wound environment. The validated cell banks and equipment will be transferred to Healthpoint’s cell-based manufacturing facility in Lausanne, Switzerland, which is authorized by Swissmedic (the Swiss Regulatory Agency) for the production of both allogeneic (i.e., derived outside of patient’s own body) cell therapies and autologous (i.e., derived from patient’s own body) tissue products.